Literature DB >> 32917352

Disease course and prognosis of pleuroparenchymal fibroelastosis compared with idiopathic pulmonary fibrosis.

Yuzo Suzuki1, Tomoyuki Fujisawa2, Hiromitsu Sumikawa3, Tomonori Tanaka4, Chikatoshi Sugimoto5, Masato Kono6, Hironao Hozumi2, Masato Karayama2, Kazuki Furuhashi2, Noriyuki Enomoto2, Yutaro Nakamura2, Naoki Inui2, Takafumi Suda2.   

Abstract

BACKGROUND: Idiopathic pleuroparenchymal fibroelastosis (iPPFE) is a rare interstitial lung disease characterized by unique radiological and pathological findings. However, pathological evaluations are available only in a limited number of patients. Therefore, several clinical diagnostic criteria have been proposed. Nevertheless, the applicability of these criteria has not yet been validated. Moreover, the clinical course of iPPFE and its prognosis have not yet been completely elucidated.
METHODS: The present study assessed previously proposed clinical diagnostic criteria by comparing the clinical features between pathologically diagnosed iPPFE (p-iPPFE) and clinically diagnosed iPPFE (c-iPPFE). Subsequently, the clinical features of iPPFE were characterized and compared with those of idiopathic pulmonary fibrosis (IPF, n = 323).
RESULTS: Clinical characteristics of c-iPPFE (n = 27) and p-iPPFE (n = 35) were similar. No significant difference was observed in terms of prognosis between c-iPPFE and p-iPPFE. The number of patients with iPPFE (both c-iPPFE and p-iPPFE) who developed lung cancer was significantly lower than that of patients with IPF. However, acute exacerbation (AE) showed similar incidence in patients with iPPFE and IPF. Survival of patients with iPPFE was significantly worse than that of patients with IPF (5-year survival rate: 38.5% vs. 63.5%, p < 0.0001), and the most common cause of death was chronic respiratory failure (73.8%), followed by AE (14.3%). Male gender was the only poor prognostic factor of iPPFE.
CONCLUSION: The present study demonstrated efficiency of clinical diagnosis and also revealed clinically important characteristics of iPPFE that should be considered for management of iPPFE.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute exacerbation; Clinical diagnosis; Idiopathic pulmonary fibrosis; Pleuroparechymal fibroelastosis; Prognosis

Mesh:

Year:  2020        PMID: 32917352     DOI: 10.1016/j.rmed.2020.106078

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  8 in total

1.  Lung involvement during the prediagnostic phase of idiopathic pleuroparenchymal fibroelastosis.

Authors:  Takuto Miyamura; Yoshiaki Kinoshita; Hisako Kushima; Hiroshi Mukae; Hiroshi Ishii
Journal:  ERJ Open Res       Date:  2022-05-09

2.  Standardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis.

Authors:  Yuko Tanaka; Yuzo Suzuki; Hirotsugu Hasegawa; Koshi Yokomura; Atsuki Fukada; Yusuke Inoue; Hironao Hozumi; Masato Karayama; Kazuki Furuhashi; Noriyuki Enomoto; Tomoyuki Fujisawa; Yutaro Nakamura; Naoki Inui; Takafumi Suda
Journal:  Respir Res       Date:  2022-06-01

Review 3.  The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis.

Authors:  Yoshiaki Kinoshita; Hiroshi Ishii; Kazuki Nabeshima; Kentato Watanabe
Journal:  Histol Histopathol       Date:  2020-12-14       Impact factor: 2.303

4.  Physiological Criteria Are Useful for the Diagnosis of Idiopathic Pleuroparenchymal Fibroelastosis.

Authors:  Takato Ikeda; Yoshiaki Kinoshita; Yusuke Ueda; Tomoya Sasaki; Hisako Kushima; Hiroshi Ishii
Journal:  J Clin Med       Date:  2020-11-22       Impact factor: 4.241

5.  Idiopathic pleuroparenchymal fibroelastosis: first case report in Lebanon.

Authors:  Nagham Bazzi; Sally Mansour; Aly Masry; Ahmad Shahrour; Bassam Mansour
Journal:  J Surg Case Rep       Date:  2021-11-29

6.  Radiological pleuroparenchymal fibroelastosis-like lesion in idiopathic interstitial pneumonias.

Authors:  Tomoyuki Fujisawa; Yasuoki Horiike; Ryoko Egashira; Hiromitsu Sumikawa; Tae Iwasawa; Shoichiro Matsushita; Hiroaki Sugiura; Kensuke Kataoka; Mikiko Hashisako; Hideki Yasui; Hironao Hozumi; Masato Karayama; Yuzo Suzuki; Kazuki Furuhashi; Noriyuki Enomoto; Yutaro Nakamura; Naoki Inui; Takafumi Suda
Journal:  Respir Res       Date:  2021-11-11

7.  Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.

Authors:  Yuzo Suzuki; Kazutaka Mori; Yuya Aono; Masato Kono; Hirotsugu Hasegawa; Koshi Yokomura; Hyogo Naoi; Hironao Hozumi; Masato Karayama; Kazuki Furuhashi; Noriyuki Enomoto; Tomoyuki Fujisawa; Yutaro Nakamura; Naoki Inui; Hidenori Nakamura; Takafumi Suda
Journal:  BMC Pulm Med       Date:  2021-07-12       Impact factor: 3.317

8.  A proposed prognostic prediction score for pleuroparenchymal fibroelastosis.

Authors:  Yoshiaki Kinoshita; Takato Ikeda; Takuto Miyamura; Yusuke Ueda; Yuji Yoshida; Hisako Kushima; Masaki Fujita; Takashi Ogura; Kentaro Watanabe; Hiroshi Ishii
Journal:  Respir Res       Date:  2021-07-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.